wepbound.com

Tag: innovation funds

  • **Which Is the Best Innovation Fund? The Data, Trade-Offs, and Hard Truths**

    **Which Is the Best Innovation Fund? The Data, Trade-Offs, and Hard Truths**

    Header image source: Innovation Fund: FAQs on the upcoming first call for proposals – Forest-based Sector Technology Platform (FTP) via Forest-based Sector Technology Platform (FTP) via Google — cropped to 16:9 and colour-adjusted.

    Key takeaways

    • Bandhan Innovation Fund leads India with 19.09% annual returns
    • Fundrise Innovation Fund offers illiquid private tech startup exposure
    • ARKK crashed after interest rate hikes – macro conditions matter

    Bandhan Innovation Fund just posted 19.09% returns over the last year. That’s not just good—it’s the highest among India’s 13 innovation-themed mutual funds.

    The Short-Term Winners: Performance of India’s Innovation Themed Funds

    Here’s the raw data from Value Research’s 13 innovation-themed funds:

    • Bandhan Innovation Direct: 19.09%
    • HDFC Innovation Direct: 16.28%
    • Axis Innovation Direct: 15.57%
    • ICICI Pru Innovation Direct: (return not specified in brief)
    • Baroda BNP Paribas Innovation Direct: 10.62%

    No fund in the category posted negative returns over the last year. Bandhan’s top holdings include technology companies that benefit from enterprise AI adoption.

    And with expense ratios that can be substantial, you’re paying a premium for concentrated exposure.

    Beyond Thematic Funds: The Broader Innovation Fund Universe

    • Allspring Innovation Fund
    • AlphaCentric Robotics and Automation Fund
    • American Beacon ARK Transformative Innovation Fund
    • Berkshire Focus Fund

    The Allspring Innovation Fund, for example, blends innovation themes with broader growth stocks.

    Then there are Fidelity’s growth funds, which are listed among the best mutual funds of 2026:

    • Fidelity Blue Chip Growth (FBGRX): Focused on large growth companies.
    • Fidelity Growth Company Fund (FDGRX): More mid-cap exposure.
    • Fidelity Mega Cap Stock Fund (FGRTX): Focused on established large-cap companies.

    FBGRX, for example, has significant tech exposure but also diversification across other sectors.

    Fundrise Innovation Fund: The Illiquid, Long-Term Play

    Fundrise just launched its Innovation Fund, moving beyond real estate into private tech startups. This isn’t a mutual fund or ETF—it’s a long-term, illiquid bet on private-market growth.

    The strategy? Invest in private tech startups that aren’t yet public. Fundrise targets private companies with high growth potential.

    Fundrise offers repurchase programs, but there’s no guarantee of when they will occur. Right now, there’s zero penalty for liquidating, but that could change. And unlike real estate, private tech assets are less liquid—you can’t just sell a stake in a Series B startup on a whim.

    Fundrise’s Innovation Fund aims to target high-growth tech.

    Costs Matter: Expense Ratios and Hidden Fees

    Here’s a dirty secret: market indexes don’t include expenses.

    Innovation ETFs have varying expense ratios. That’s not negligible—over time, fees can significantly erode your returns.

    Thematic mutual funds like Bandhan Innovation Direct and HDFC Innovation Direct charge expense ratios. At higher expense ratios, you’re paying significant amounts just for the privilege of holding the fund.

    ARKK’s expense ratio might be worth it if its picks outperform, but after significant declines, that’s debatable. Meanwhile, low-cost ETFs include innovation stocks alongside everything else.

    Liquidity vs. Growth: The Core Trade-Off

    Diversification: Thematic Funds vs. Broad Innovation Exposure

    | Fund Type | Diversification | Risk Level | Best For |

    | Thematic (Bandhan, ARKK)| Low | High | Speculative bets | | Broad Growth (FBGRX) | High | Medium | Long-term investors | | ETFs (ARKK, BOTZ) | Medium | Medium | Low-cost exposure | | Fundrise Innovation | Low | High | Illiquid, long-term growth |

    They’re too risky for core holdings. Instead, use ETFs or broad growth funds for innovation exposure, and limit thematic funds to small satellite positions. Thematic funds can juice returns, but they can also destroy them. Treat them like spices—useful in small doses, dangerous in excess.

    The ARK Effect: Lessons from High-Risk Innovation Funds

    ARK Innovation ETF (ARKK) was the poster child for innovation funds—until it wasn’t. It peaked at a high price, then crashed significantly over the next year. Why? Overconcentration in growth stocks.

    Cathie Wood’s thesis was growth at any price. When interest rates rose, discount rates killed valuations, and ARKK’s holdings collapsed. The fund is still down significantly from its peak. That’s not a blip—it’s a permanent loss of capital for anyone who bought at the top.

    The lesson? Even top-performing innovation funds can fail. Their success depends on macro conditions (low interest rates) and narrative momentum (AI, crypto, etc.). When those shift, they crash hard. ARKK’s rise and fall wasn’t about skill—it was about being in the right place at the right time.

    Investors should limit thematic funds to 5-10% of their portfolio. They’re speculative tools, not core holdings. If you’re going to bet on a thematic fund, do it with money you can afford to lose. And don’t mistake a bull market for genius.

    The Final Verdict: How to Pick the "Best" Innovation Fund

    There’s no universal "best" innovation fund—just the one that fits your goals. Here’s how to choose:

    1. For liquidity and low cost:
    • Innovation ETFs (ARKK, BOTZ) or broad growth funds (Fidelity Blue Chip Growth).
    • Why? Daily trading, lower fees, and diversification. These are the default choices for most investors.
    1. For short-term outperformance:
    • Bandhan Innovation Fund (if in India) or Allspring Innovation Fund (U.S.).
    • Why? Highest recent returns, but high risk. These are bets, not investments.
    1. For illiquid, long-term growth:
    • Fundrise Innovation Fund (but only with a 5+ year horizon).
    • Why? Private-market exposure, but no liquidity. This is venture capital for the masses—high reward, but high risk.
    1. For diversification:
    • Avoid pure thematic funds. Opt for ETFs or broad growth funds instead.
    • Why? Thematic funds are too volatile for most investors. Diversification isn’t just a buzzword—it’s risk management.

    The "best" fund is context-dependent. If you’re a long-term investor with high risk tolerance, Fundrise or Bandhan could work. If you need liquidity and diversification, stick to ETFs or Fidelity’s growth funds. And if you’re unsure, start with a low-cost ETF and add thematic exposure later.

    The real question isn’t "Which fund is best? "—it’s "Which fund fits my goals, risk tolerance, and time horizon? " Answer that, and you’ll have your pick. But don’t mistake a fund’s recent performance for a permanent edge. Markets change, trends fade, and yesterday’s winner is often tomorrow’s loser. The only sustainable strategy is one that aligns with your needs—not the fund’s marketing.

    Sources

  • **Is It Good to Invest in an Innovation Fund? The Data, Risks, and Real Returns**

    **Is It Good to Invest in an Innovation Fund? The Data, Risks, and Real Returns**

    Header image: Bioscience Innovation Act bill signing ceremony (9672310549).jpg) by Dannel Malloy, CC BY 2.0, via Wikimedia Commons — cropped to 16:9 and colour-adjusted.

    Key takeaways

    • Innovation funds can outperform indices but require long-term commitment and risk tolerance.
    • Domestic funds like ICICI Pru focus on Indian innovation, while global funds offer broader exposure.
    • Allocate only 3-5% of your portfolio to innovation funds as a satellite holding.

    Here’s the short answer: Yes, but only if you meet very specific conditions. Innovation funds can deliver outsized returns—Kotak Pioneer Fund returned 36.4% over three years compared to 31.75% for the Nifty 500 TRI—but they are not "safe" investments. Their success depends on geographic diversification, stage-specific bets, manager expertise, and your ability to stomach volatility. If you’re not prepared for 20–30% drawdowns, lack a 5–10+ year horizon, or haven’t already maxed out diversified funds like index funds, walk away. For everyone else, innovation funds belong as a small satellite holding—think 3–5% of your portfolio, not the core.

    The Surge in Innovation Funds: Why 2024 Is Different

    April 2024 saw a flurry of innovation fund launches: ICICI Prudential, Bandhan Mutual Fund, and Nippon Life all rolled out new offerings. This wasn’t random timing. The Federal Reserve and RBI are normalizing interest rates, and history shows that lower rates favor growth stocks—exactly the kind of companies innovation funds target.

    But here’s the catch: These 2024 launches are overwhelmingly domestic-focused. ICICI Pru’s Innovation Fund, for example, is "more domestic-focused" according to critics, despite allowing overseas securities. Bandhan’s fund doesn’t even disclose its allocation strategy. Meanwhile, three global ‘fund of funds’ (Axis, DSP and Kotak) already exist, offering broader exposure to global innovators. The domestic funds? They’re betting on Indian companies adopting innovation, not necessarily global leaders driving it.

    How These Funds Are Structured

    • ICICI Pru Innovation Fund:
    • Minimum 80% in innovation-adopting companies, including overseas securities.
    • Targets three stages of innovation:
    1. Initial research/product development (highest risk, e.g., unproven biotech).
    2. Pre-launch/testing (moderate risk, e.g., beta-stage SaaS).
    3. Launch/post-launch (lower risk, e.g., scaling fintech).
    • Nippon Life Innovation Fund:
    • Multi-cap, with a bias toward low-leverage, high-profitability growth firms. This reduces bankruptcy risk but may exclude cash-burning disruptors (e.g., early-stage EV startups).
    • Bandhan Innovation Fund:
    • Launched the same day as ICICI Pru’s NFO (April 10, 2024), but no specifics on allocation or strategy have been disclosed.

    The takeaway? If you’re going to invest, scrutinize the fund’s exposure. Domestic-only funds are narrower and riskier than global ones, and stage-specific bets (early vs. late) drastically alter the risk/reward profile.

    Where Innovation Funds Win: The Outperformance Case

    The strongest argument for innovation funds is their potential to outperform broad-market indices. Kotak Pioneer Fund’s 36.4% 3-year return (vs. 31.75% for the Nifty 500) isn’t an anomaly—it’s a proof point that targeted innovation exposure can work.

    Three Key Advantages

    1. Access to Early-Stage Disruptors
    • ICICI Pru’s fund includes pre-launch/testing-stage companies, which are high-risk but high-reward. Think of a startup with a breakthrough AI model—unproven but potentially revolutionary.
    • Nippon Life’s low-leverage, high-profitability filter may reduce bankruptcy risk while still capturing scaling innovators (e.g., profitable SaaS companies).
    1. Diversification Within Innovation
    • Unlike single-sector funds (e.g., pure-play AI ETFs), innovation funds span multiple themes—AI, biotech, fintech, cleantech. This reduces sector-specific risk (e.g., if biotech crashes but AI soars).
    1. Thematic Tailwinds
    • Innovation isn’t cyclical—it’s structural. AI, automation, and biotech are long-term trends, not fads. Funds that get in early (like Kotak Pioneer did in 2019) can ride these waves for years.

    Real-World Example: Fundrise Innovation Fund

    • Open to all US investors (not just accredited).
    • One investor allocated 3.5% of their portfolio to it and called it "a worthwhile investment"—their largest gains came from this fund.
    • Unlike Indian funds, Fundrise blends public and private innovation bets, giving exposure to pre-IPO disruptors.

    Where Innovation Funds Fall Short: The Hard Truths

    For every success story, there’s a hidden risk—and innovation funds have plenty.

    1. Narrow Focus = Higher Volatility

    • Thematic funds underperform in downturns. In 2022, tech-heavy innovation funds crashed harder than the Nifty 500. If you can’t stomach a 20–30% drawdown, you’re not cut out for this.
    • No international exposure in domestic funds is a major flaw. Critics argue Nippon Life’s fund should include US cutting-edge companies.g., Nvidia, Moderna). Missing global leaders means missing the biggest innovators.**

    2. Liquidity Risks

    • Innovation funds are intended as long-term investments with less liquid assets than diversified funds. Fundrise, for example, holds private companies—you can’t sell those overnight.
    • If you might need cash in less than 5 years, this isn’t the place for it.

    3. Manager Dependency

    • "Any fund is only as good as the people managing it. " This isn’t just criticism—it’s reality. Poor stock-picking can erase alpha. For example:
    • If ICICI Pru’s fund bets heavily on failed startups, returns will suffer.
    • Nippon Life’s profitability filter might exclude high-growth, cash-burning disruptors (e.g., early-stage EV companies).

    4. Timing Risk

    These funds launched in 2024 as a normalising interest rate environment appears on the cards. What happens if rates stay high? Growth stocks suffer. 2022 proved that.**

    Geographic Exposure: The Domestic vs. Global Divide

    | Fund | Overseas Exposure? | Pros | Cons | |———————–|——————–|——————————-|——————————-| | ICICI Pru Innovation | Yes (but domestic-focused) | Avoids currency risk | Misses global leaders (Nvidia, Moderna) | | Bandhan Innovation | Unknown | Simpler regulatory hurdles | Likely no global exposure | | Nippon Life Innovation | No | Lower geopolitical risk | Critics would have liked to add overseas exposure to companies in cutting-edge spaces in the US | | Kotak Pioneer | Via fund structure | Access to innovation funds | Higher fees, currency risk | | Fundrise (US) | Yes (US-focused) | Blends public/private bets | Illiquid private holdings |

    The verdict?

    • If you want pure innovation exposure, global funds (Kotak, Fundrise) are stronger.
    • If you prefer simplicity and lower fees, domestic funds (ICICI Pru, Nippon) are an option—but you’re sacrificing global leaders.

    Stage-Specific Bets: How Much Risk Are You Taking?

    ICICI Pru’s three-stage framework is a masterclass in risk stratification. Here’s how it breaks down:

    | Stage | Risk Level | Example | Upside Potential | |—————————|————|—————————–|——————| | Initial research/product development | Highest | Unproven biotech startup | 10x+ if successful | | Pre-launch/testing | Moderate | Beta-stage SaaS company | 3–5x | | Launch/post-launch | Lower | Scaling fintech | 2–3x |

    Nippon Life’s approach is different:

    • Low leverage + high profitability = reduced bankruptcy risk.
    • But it may exclude cash-burning disruptors (e.g., early-stage EV companies).

    The trade-off?

    • Early-stage = higher upside but higher failure rate.
    • Post-launch = steadier but less alpha.

    Which is better? It depends on your risk tolerance. If you want home-run potential, early-stage is key. If you prefer lower volatility, post-launch is safer.

    The Competition: How Do These Funds Stack Up?

    | Fund | Launch Date | Min. Allocation to Innovation | Overseas Exposure? | Stage Focus | 3-Year Return (if available) | |———————–|————-|——————————-|——————–|———————-|——————————| | ICICI Pru Innovation | Apr 2024 | 80% | Yes (but domestic-focused) | All three stages | N/A | | Bandhan Innovation | Apr 2024 | N/A | Unknown | Unknown | N/A | | Nippon Life Innovation | 2024 | N/A | No | Multi-cap, growth | N/A | | Kotak Pioneer | Oct 2019 | N/A | Unknown | Unknown | 36.4% | | Fundrise Innovation | Unknown | Unknown | Yes (US-focused) | Unknown | Top performer for one investor |

    Key takeaways:

    • Global funds (Kotak, Fundrise) offer broader exposure but come with higher fees and currency risk.
    • Domestic funds (ICICI Pru, Nippon) are narrower but simpler—but critics argue they miss global leaders.
    • Stage-specific funds (ICICI Pru) let you choose your risk level, while profitability-focused funds (Nippon) reduce bankruptcy risk.

    The Investor Profile: Who Should (and Shouldn’t) Invest?

    ✅ Good Fit If You:

    • Have a 5–10+ year horizon (innovation is a long game).
    • Can handle 20–30% drawdowns (e.g., 2022’s tech crash).
    • Allocate less than 5% of your portfolio (e.g., the 3.5% Fundrise investor).
    • Already maxed out diversified funds (e.g., Nifty 500 index).

    ❌ Bad Fit If You:

    • Need liquidity (innovation funds are illiquid).
    • Are risk-averse (these are not "safe" investments).
    • Lack manager trust (poor stock-picking kills returns).
    • Haven’t diversified your core holdings (innovation funds are satellite holdings, not replacements for index funds).

    The Bottom Line: How to Invest in Innovation (If at All)

    If you’re still reading, you’re serious about innovation funds. Here’s how to do it right:

    1. Pick Global Exposure (If Possible)

    • Kotak Pioneer Fund (via FoF) or Fundrise Innovation Fund (US-focused) give you global leaders (Nvidia, Moderna, etc.).
    • If you must go domestic, ICICI Pru’s fund (which allows overseas securities) is the best option.

    2. Diversify Across Innovation Stages

    • ICICI Pru’s three-stage approach lets you balance early-stage risk with post-launch stability.
    • If you want lower volatility, Nippon Life’s profitability filter reduces bankruptcy risk.

    3. Limit to 3–5% of Your Portfolio

    • Innovation funds are high-risk, high-reward. 3.5% (like the Fundrise investor) is a smart allocation—enough to move the needle, but not enough to wipe you out.

    4. Check the Manager’s Track Record

    • "Any fund is only as good as the people managing it. " Look for:
    • Past performance (e.g., Kotak Pioneer’s 36.4% return).
    • Sector expertise (does the team understand AI, biotech, etc.?).
    • Risk management (does the fund avoid reckless bets?).

    Alternatives to Consider

    If innovation funds feel too risky, here are lower-risk ways to play innovation:

    • Diversified growth funds (e.g., Nifty Next 50) for broader exposure.
    • Sector-specific ETFs (e.g., AI, biotech) for targeted bets.
    • Venture capital (VC) funds (if accredited) for higher-risk, higher-reward private innovation.

    Final Question: Is the Juice Worth the Squeeze?

    Innovation funds can outperform—but only under the right conditions. If you:

    • Have a long time horizon,
    • Can stomach volatility,
    • Allocate wisely (3–5%), and
    • Pick the right fund (global exposure, strong manager),

    …then yes, they’re worth it.

    But if you’re looking for stability, liquidity, or "safe" returns, keep walking. Innovation funds are not for the faint of heart—they’re for investors who understand the risks and can afford to wait.

    So, is it good to invest in an innovation fund? Only if you’re prepared to lose money for years before (hopefully) winning big. If that’s not you, stick to index funds. If it is? Dive in—but not with more than 5% of your portfolio. The real question is: Are you ready for the ride?

    Sources